Course curriculum
-
-
Acromegaly - 2Qs (May 2023)
-
Alcohol use and cancer risk (March 2021)
-
Alpha-1 reductase inhibitors and prostate cancer (May 2021)
-
Anal intraepithelial neoplasia and cancer - 3Qs (July 2018)
-
Basal cell carcinoma - 2Qs (September 2020)
-
Borderline ovarian tumors - 3Qs (January 2022)
-
Brain tumors in children (November 2022)
-
BRCA1/2 gene testing (July 2022)
-
Breast cancer - chemoprophylaxis - 3Qs (September 2022)
-
Breast cancer - chemoprophylaxis - 3Qs (November 2020)
-
Breast cancer - chemoprophylaxis - 3Qs (July 2019)
-
Breast cancer in men - 3Qs (May 2019)
-
Breast cancer in trans adults - 2Qs (September 2022)
-
Breast cancer - Genitourinary symptoms - 3Qs (January 2019)
-
Breast cancer - modifiable risk factors (November 2021)
-
Breast cancer survivors - Chronic side effects - 4Qs (July 2018)
-
Breast cancer – triple negative - 4Qs (May 2019)
-
Breast imaging of dense breasts (January 2023)
-
Cell-free DNA testing (May 2019)
-
Cervical adenopathy (May 2023)
-
Cervical adenopathy - 2Qs (March 2020)
-
Cervical cancer screening - 2Qs (September 2018)
-
Chronic lymphocytic leukemia (May 2023)
-
Chronic lymphocytic leukemia - 5Qs (July 2020)
-
Classic Hodgkin lymphoma - 5Qs (May 2020)
-
Common variable immunodeficiency (March 2022)
-
Cutaneous squamous cell carcinoma (March 2019)
-
Diethelstibestrol exposure (September 2022)
-
Endometrial cancer - 5Qs (November 2020)
-
Endometrial polyps - 2Qs (March 2023)
-
Esophageal cancer (November 2021)
-
Esophageal cancer - 5Qs (March 2020)
-
Evaluation of bone metastases (January 2023)
-
Ewing sarcoma (January 2019)
-
Gallbladder cancer (January 2022)
-
Gallbladder polyps - 2Qs (May 2020)
-
Gastric cancer (July 2022)
-
Gestational trophoblastic disease (January 2019)
-
Hepatocellular carcinoma - 4Qs (January 2022)
-
Hepatocellular carcinoma - 2Qs (September 2018)
-
High-grade cervical squamous intraepithelial lesion (July 2018)
-
Hodgkin lymphoma - 2Qs (September 2021)
-
HPV infection counseling (July 2022)
-
HPV-related cancers - 3Qs (November 2021)
-
Inflammatory bowel disease and risk of colon cancer (January 2020)
-
Kaposis sarcoma (July 2021)
-
Localized prostate cancer (July 2019)
-
Lung cancer - 4Qs (January 2019)
-
Lung cancer in nonsmokers - 3Qs (September 2019)
-
Lung cancer - screening (September 2022)
-
Lung cancer screening - 3Qs (November 2021)
-
Melanoma - 2Qs (July 2019)
-
Melanoma overview - 2Qs (September 2021)
-
Melanoma in skin of color - 2Q (September 2021)
-
Melanoma types - 3Qs (September 2021)
-
Meningioma (March 2020)
-
Mesothelioma (July 2021)
-
Microscopic hematuria (July 2018)
-
Multiple endocrine neoplasia - 4Qs (January 2022)
-
Non-Hodgkin lymphoma - 6Qs (May 2022)
-
Non-lipid statin use - 2Qs (November 2021)
-
Oral neoplasms - 2Qs (May 2020)
-
Paget's disease of the breast - 2Qs (September 2021)
-
Pancreatic cancer -3Qs (March 2021)
-
Pancreatic cancer screening (January 2020)
-
Prostate cancer – chemoprevention (May 2019)
-
Prostate cancer - treatment options - 4Qs (September 2020)
-
Rectal cancer - 5Qs (November 2020)
-
Seizure and headache in a middle-aged man - 4Qs (November 2019)
-
Syndrome of inappropriate antidiuretic hormone (SIADH) - 3Qs (November 2021)
-
Tamoxifen - 2Qs (November 2022)
-
Testicular cancer (May 2022)
-
Thyroid cancer - 2Qs (July 2022)
-
Transgender breast cancer risk and screening (September 2020)
-
Triple negative breast cancer (September 2021)
-
Unprovoked venous thrombosis - 4Qs (November 2019)
-
Venous thromboembolism and malignancy - 2Qs (January 2019)
-
About this course
- Free
- 77 lessons
- 0 hours of video content